Recursion Pharmaceuticals Inc. (RXRX) Social Stream



Recursion Pharmaceuticals Inc. (RXRX): $9.47

0.10 (+1.07%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RECURSION PHARMACEUTICALS INC (RXRX) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering RECURSION PHARMACEUTICALS INC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-11 5 $37 $30 $33.5 $8.22 307.54%
2021-12-07 5 $37 $30 $33 $8.22 301.46%
2021-12-08 5 $37 $31 $34.2 $8.22 316.06%
2022-01-14 5 $37 $28 $32.8 $8.22 299.03%
2022-03-04 5 $37 $10 $28.4 $8.22 245.5%
2022-05-10 4 $37 $10 $22 $8.22 167.64%
2022-05-12 4 $37 $10 $18.25 $8.22 122.02%
2022-05-18 4 $37 $9 $18 $8.22 118.98%
2022-08-09 5 $37 $7 $15.8 $8.22 92.21%
2022-08-13 5 $37 $8 $16 $8.22 94.65%
2022-08-23 5 $37 $8 $16.2 $8.22 97.08%
2022-09-10 6 $37 $8 $16.2 $8.22 97.08%
2022-09-17 6 $37 $8 $16.833 $8.22 104.78%
2022-11-08 5 $20 $8 $13 $8.22 58.15%
2022-11-11 5 $20 $9 $13.2 $8.22 60.58%
2022-11-17 5 $20 $9 $13.4 $8.22 63.02%
2023-01-23 5 $20 $8 $13.2 $8.22 60.58%

The Trend in the Analyst Price Target


RXRX's average price target has moved down $19.2 over the prior 17 months.

RXRX reports an average of 115.35% for its upside potential over the past 46 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-04-18 4 37 10 22.0 6.53 236.91%
2022-05-18 5 37 9 18.0 5.62 220.28%
2022-08-09 5 37 7 15.8 8.81 79.34%
2022-09-17 5 20 8 12.8 10.80 18.52%
2022-09-17 6 20 8 12.8 10.80 18.52%

RXRX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.6 1 0 4 0 0 5

The Trend in the Broker Recommendations


Over the past 16 months, RXRX's average broker recommendation rating worsened by 0.8.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • In the context of all US stocks, RECURSION PHARMACEUTICALS INC's variance in analysts' estimates is lower than -1527.21% of them.
  • In terms of how RECURSION PHARMACEUTICALS INC fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 1643.34% of that group.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, RECURSION PHARMACEUTICALS INC's number of analysts covering the stock is higher than 497.18% of them.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, RECURSION PHARMACEUTICALS INC's average analyst price target is higher than 536.59% of them.

Stocks similar to RECURSION PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EXAI, SNDL, and HEXO.

What is the outlook for RXRX? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 21.3457 seconds.